BioPharmX Corporation, a specialty pharmaceutical company, announced that research being presented at the 2016 Winter Clinical Dermatology Conference shows its unique formulation of minocycline, known as BPX-01, may offer a

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field